11-Amino-12-oxo-1-azatricyclo[6.4.1.04,13]trideca-4,6,8(13)-triene-2-carboxylic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 11-Amino-12-oxo-1-azatricyclo[6.4.1.04,13]trideca-4,6,8(13)-triene-2-carboxylic acid
• 化学式: C₁₃H₁₄N₂O₃
• 分子量: 246.26
• InChiKey: KCYCGNHQFGTGSS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.8
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  83.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Tetrapeptide analogs
  申请人：Chao Bin

  公开号：US20100190688A1

  公开（公告）日：2010-07-29

  Compounds, compositions and methods for treatment of hyperproliferative diseases, such as cancer are provided.

  提供了用于治疗过度增殖性疾病，如癌症的化合物、组合物和方法。
• Tripeptides as caspase modulators
  申请人：Idun Pharmaceuticals, Inc.

  公开号：EP2457896A1

  公开（公告）日：2012-05-30

  Compounds, compositions and methods for treatment of hyperproliferative diseases, such as cancer are provided. or a pharmaceutically acceptable derivative thereof, where: M is CO, SO or SO2; R1sand R2s are selected as follows: (i) R1s is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocyclyI; and R2s is selected from hydrogen, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, OR11 and NR15R16, or (ii) R 1sand R2s together with the nitrogen atom on which they are substituted form a heterocyclic or heteroaryl ring; R3s, R4s and R5s are each independently selected from (i) or (ii) as follows: (i) R3s is hydrogen or alkyl; R4s is alkyl; and R5s is selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroarylium, cycloalkyl, heterocyclyl and NR15R16; (ii )R5s and R3s or R5s and R4s together with the atoms on which they are substituted form heterocyclic or heteroaryl ring and the other of R3s or R4s is selected as (ii); R6s is hydrogen, lower alkyl, lower alkenyl or lower alkynyl; R7s is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocyclyl. The other variables are as defined in the claims.

  本研究提供了用于治疗过度增殖性疾病（如癌症）的化合物、组合物和方法。 或其药学上可接受的衍生物、 其中 M 是 CO、SO 或 SO2； R1s 和 R2s 选取如下： (i) R1s 是氢、烷基、烯基、炔基、芳基、杂芳基、环烷基或杂环烷基；R2s 选自氢、烯基、炔基、芳基、杂芳基、环烷基、杂环烷基、 OR11 和 NR15R16，或 (ii) R 1s 和 R2s 与它们被取代的氮原子一起形成杂环或杂芳基环； R3s、R4s 和 R5s 各自独立地选自如下的 (i) 或 (ii)： (i) R3s 是氢或烷基；R4s 是烷基；R5s 选自氢、烷基、烯基、炔基、芳基、杂芳基、杂芳脲基、环烷基、杂环烷基和 NR15R16； (ii)R5s 和 R3s 或 R5s 和 R4s 与它们被取代的原子一起形成杂环或杂芳基环，且 R3s 或 R4s 中的另一个选为(ii)； R6s 是氢、低级烷基、低级烯基或低级炔基； R7s 是氢、烷基、烯基、炔基、芳基、杂芳基、环烷基或杂环烷基。 其他变量如权利要求中所定义。
• Method for producing an examination reagent and kit for analysing a T-cell frequency
  申请人：JACOBS UNIVERSITY BREMEN GGMBH

  公开号：US10386367B2

  公开（公告）日：2019-08-20

  A method for producing an examination reagent includes adding a helper ligand to an unfolded receptor protein in an initial solution so as to provide a pre-solution of the examination reagent with a folded receptor protein. The folded receptor protein comprises a bonded helper ligand which can be exchanged with an examination peptide.

  生产检查试剂的方法包括在初始溶液中向未折叠的受体蛋白中加入辅助配体，以提供带有折叠受体蛋白的检查试剂预溶液。折叠后的受体蛋白包含一个可与检查肽交换的键合辅助配体。
• EP1773348A4
  申请人：——

  公开号：EP1773348A4

  公开（公告）日：2009-05-20
• TETRAPEPTIDE ANALOGS
  申请人：Idun Pharmaceuticals, Inc.

  公开号：EP1773348A2

  公开（公告）日：2007-04-18